Letters and Statements

ACCC sent a letter to House and Senate leaders this week, encouraging Congress to take action before the end of this year to mitigate significant Medicare payment cuts and improve patient access to high quality, efficient, and equitable cancer care. Without congressional intervention, significant reductions to Medicare payment will take effect in January 2023, including the proposed 4.42% reduction to the Medicare Physician Fee Schedule conversion factor and 4% Statutory Pay-As-You-Go sequester. Additional priorities include supporting the transition to value-based care, extending telehealth flexibilities beyond the COVID-19 public health emergency, and improving prior authorization processes in the Medicare Advantage program.
Read the Letter

In a letter to U.S. Food and Drug Administration (FDA) Commissioner Robert Califf, M.D., ACCC raises concern about recent delays in inspections of manufacturing facility that have led to interruptions in the approval of breakthrough therapies. We are particularly concerned when these delays impact novel treatments for diseases without FDA-approved therapies available and those that disproportionately impact minority communities.
Read the Letter